Table 1.
Baseline characteristics of the study population
| AF patients (n = 94) | Healthy controls (n = 19) | P-value | |
|---|---|---|---|
| Demographics | |||
| Age, years | 60 ± 9 | 58 ± 4 | 0.21 |
| Male gender | 60 (64%) | 11 (58%) | 0.63 |
| Weight (kg) | 84 ± 14 | 80 ± 12 | 0.44 |
| Height (cm) | 180 ± 11 | 176 ± 8 | 0.15 |
| BMI (kg/m2) | 25.9 ± 3.4 | 25.6 ± 5.1 | 0.84 |
| BSA (Mosteller)* | 2.0 ± 0.2 | 2.0 ± 0.2 | 0.48 |
| CHA2DS2-VASc score | 1.2 ± 1.2 | – | – |
| Hypertension | 30 (32%) | – | – |
| Diabetes mellitus | 4 (4%) | – | – |
| Medications | |||
| ACE inhibitor or ARB | 29 (30.9%) | – | – |
| Spironolactone | 3 (3.2%) | – | – |
| Amiodarone | 10 (11.0%) | – | – |
| Anticoagulation | 77 (81.9%) | – | – |
| AF history | |||
| Paroxysmal AF | 62 (66%) | – | – |
| Persistent AF | 32 (34%) | – | – |
| Time between AF diagnosis and CMR (months) | 32 (14–83) | – | – |
Values are expressed as number (percentage), mean ± SD or median (25–75th percentile). ACE angiotensin-converting-enzyme, ARB Angiotensin-receptor-blocker, AF atrial fibrillation, BMI body mass index, BSA body surface area, CHA2DS2VASc history of congestive heart failure, hypertension, diabetes mellitus, stroke/transient ischemic attack/prior thromboembolism, vascular disease, age and sex, CMR cardiovascular magnetic resonance. *Calculated by the Mosteller method ((height (cm) x weight (kg)/3600)½)